Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.36 |
| ▸ | SCN5A | Q14524 | 2/20 | 0.36 |
| ▸ | MAP2K4 | P45985 | 1/20 | 0.34 |
| ▸ | THRB | P10828 | 1/20 | 0.34 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.33 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.33 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.32 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.32 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.32 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.32 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.32 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.32 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30574503 | 1.00 | MAPT (0.36) | MAPTTP53SCN9ASCN5AMAP2K4 | |
| SCHEMBL30574504 | 0.80 | GPR3 (0.40) | MAPTSCN9ASCN5APDE3BPDE3A | |
| SCHEMBL21294301 | 0.80 | GPR3 (0.40) | MAPTSCN9ASCN5APDE3BPDE3A | |
| SCHEMBL12365177 | 0.78 | RARA (0.46) | MAP2K4 | |
| SCHEMBL903245 | 0.76 | MAPT (0.46) | MAPTTHRB | |
| SCHEMBL17049536 | 0.76 | PDCD1 (0.39) | MAPTTHRBADRA2ACYP3A4 | |
| SCHEMBL12365106 | 0.75 | BCL2L1 (0.46) | MAPTCYP3A4 | |
| SCHEMBL16934743 | 0.74 | LSS (0.40) | MAPT | |
| SCHEMBL12365134 | 0.74 | MYC (0.43) | MAPTTP53 | |
| SCHEMBL28518379 | 0.73 | MAPT (0.36) | MAPTTP53SCN9ASCN5AMAP2K4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250346586-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | ARTAX BIOPHARMA INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12319675-B2 | Chromene derivatives as inhibitors of TCR-Nck interaction | ARTAX BIOPHARMA INC. (US) | 2025-06-03 | — | — | US | disclosed |
| US-20240199592-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | ARTAX BIOPHARMA INC. | 2024-06-20 | — | — | US | disclosed |
| CN-117304157-A | Chromene derivatives as inhibitors of TCR-NCK interactions | 阿塔克斯生物制药有限公司 | 2023-12-29 | — | — | CN | disclosed |
| US-11807633-B2 | Chromene derivatives as inhibitors of TCR-Nck interaction | ARTAX BIOPHARMA INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807633-B2 | Chromene derivatives as inhibitors of TCR-Nck interaction | ARTAX BIOPHARMA INC. (US) | 2023-11-07 | — | — | US | disclosed |
| US-11807633-B2 | Chromene derivatives as inhibitors of TCR-Nck interaction | ARTAX BIOPHARMA INC. (US) | 2023-11-07 | — | — | US | disclosed |
| CN-112189009-B | Chromene derivatives as inhibitors of TCR-NCK interactions | 阿塔克斯生物制药有限公司 | 2023-09-29 | — | — | CN | disclosed |
| US-20220081429-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | ARTAX BIOPHARMA INC. | 2022-03-17 | — | — | US | disclosed |
| US-11008310-B2 | Chromene derivatives as inhibitors of TCR-Nck interaction | ARTAX BIOPHARMA INC. (US) | 2021-05-18 | — | — | US | disclosed |
| US-11008310-B2 | Chromene derivatives as inhibitors of TCR-Nck interaction | ARTAX BIOPHARMA INC. (US) | 2021-05-18 | — | — | US | disclosed |
| CN-112189009-A | Chromene derivatives as inhibitors of TCR-NCK interaction | 阿塔克斯生物制药有限公司 | 2021-01-05 | — | — | CN | disclosed |
| US-20200347042-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | ARTAX BIOPHARMA INC. | 2020-11-05 | — | — | US | disclosed |
| US-20200347042-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | ARTAX BIOPHARMA INC. | 2020-11-05 | — | — | US | disclosed |
| US-10696663-B2 | Chromene derivatives as inhibitors of TCR-NCK interaction | ARTAX BIOPHARMA INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-10696663-B2 | Chromene derivatives as inhibitors of TCR-NCK interaction | ARTAX BIOPHARMA INC. (US) | 2020-06-30 | — | — | US | disclosed |
| US-20190263792-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | ARTAX BIOPHARMA INC. | 2019-08-29 | — | — | US | disclosed |
| US-20190263792-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | ARTAX BIOPHARMA INC. | 2019-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12319675-B2 | Chromene derivatives as inhibitors of TCR-Nck interaction | NCK1, NCKAP1, NCKAP1L | MAPT 2456/4885TP53 1419/4885SCN9A 1667/4885 |
| US-20240199592-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | NCK1, NCKAP1, NCKAP1L | MAPT 2456/4885TP53 1419/4885SCN9A 1667/4885 |
| US-20220081429-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | NCK1, NCKAP1, NCKAP1L | MAPT 2456/4885TP53 1419/4885SCN9A 1667/4885 |
| US-10696663-B2 | Chromene derivatives as inhibitors of TCR-NCK interaction | NCK1, NCKAP1, NCKAP1L | MAPT 2456/4885TP53 1419/4885SCN9A 1667/4885 |
| US-11807633-B2 | Chromene derivatives as inhibitors of TCR-Nck interaction | NCK1, NCKAP1, NCKAP1L | MAPT 2456/4885TP53 1419/4885SCN9A 1667/4885 |
| US-20200347042-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | NCK1, NCKAP1, NCKAP1L | MAPT 2456/4885TP53 1419/4885SCN9A 1667/4885 |
| US-20250346586-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | NCK1, NCKAP1, NCKAP1L | MAPT 2456/4885TP53 1419/4885SCN9A 1667/4885 |
| US-20190263792-A1 | CHROMENE DERIVATIVES AS INHIBITORS OF TCR-NCK INTERACTION | NCK1, NCKAP1, NCKAP1L | MAPT 2456/4885TP53 1419/4885SCN9A 1667/4885 |
| US-11008310-B2 | Chromene derivatives as inhibitors of TCR-Nck interaction | NCK1, NCKAP1, NCKAP1L | MAPT 2456/4885TP53 1419/4885SCN9A 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.